Novel insights into microbiome in colitis and colorectal cancer
Year: 2017
Type: review
Abstract: PURPOSE OF REVIEW: Microbiota is a major player in the pathogenesis of inflammatory bowel diseases (IBD) and colorectal cancer (CRC). Here, we summarize the key advances achieved in the past 18 months (ending June 2017) toward a better understanding of the role of microbiota in colitis and CRC development. RECENT FINDINGS: Accumulating evidence shows the essential role of intestinal barrier function (e.g. mucus, IgA, LCN2, LYPD8) in protecting against bacteria-induced inflammation and tumor development. Numerous signaling pathways (e.g. TLRs and NLRs), metabolites (e.g. indole, bile acids, retinoic acid) and small noncoding RNAs (e.g. miRNA) have been identified as key mediators regulating host-microbe interactions in the intestine. Novel microbial drivers of colitis and tumorigenesis (e.g. Alistipes finegoldii, Atopobium parvalum, Peptostreptococcus anaerobius) have been identified and their disease-promoting activities have been described. SUMMARY: IBD-associated colorectal cancer results from a complex breakdown of communication between the host and its microbiota, involving barrier function, immune signaling and metabolites.
Authors: Ye Yang, Christian Jobin
Institutions: University of Florida Health, University of Florida
Language: English
Topic: Gut microbiota and health
Subfield: Molecular Biology
Domain: Life Sciences
Keywords: gut microbiota, colitis, colorectal cancer, inflammatory bowel disease, intestinal barrier function, mucus, IgA, neutrophil gelatinase-associated lipocalin, Toll-like receptor signaling, microbial metabolites, bile acids, indole, retinoic acid, microRNA, host-microbe interactions, Alistipes finegoldii, Peptostreptococcus anaerobius, carcinogenesis
Open Access status: green
OpenAlex ID: W2751577865
